US Pharma MarketingAstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout HHS Medicaid Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home The Readout Gilead and Merck’s latest trial success and flop AstraZeneca’s GLP-1 pill, GSK’s $10.6B cancer startup acquisition, and more biotech…
Good morning. As I’ve been watching the NBA finals, every commercial break has started to sound like this.
Nuvalent is the latest biotech to be subsumed in the recent wave of pharma acquisitions, my colleague Andrew Joseph reported this morning. The company has two drugs under review by the Food and Drug Administration that target genetic mutations found in lung cancer. Approval decisions on both are expected later this year.
Source: STAT News Pharma